SKAN Stock Analysis: SKAN | SW
Medical Instruments & Supplies | SW, Switzerland | Market Cap: 1.583m CHF | 12M Return: 25.5% | CH0013396012 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.16M
Rev. Trend: 96.9%
Warnings
Tailwinds
Seasonality
SKAN Group AG, founded in 1968 and headquartered in Allschwil, Switzerland, specializes in isolators, cleanroom devices, and decontamination processes for the pharmaceutical and chemical industries, operating across Europe, the Americas, and Asia. The company runs two business segments-Equipment and Solutions, and Services and Consumables-and offers a broad portfolio ranging from laminar flow systems and safety workbenches to biological indicators, transfer systems, and digital lifecycle support services. Originally known as BV Holding AG, the company adopted its current name in October 2021.
The company sits within the health care equipment segment, supplying contamination-control technology that is essential to aseptic manufacturing of sterile pharmaceuticals, where regulatory standards (such as EU GMP and FDA guidance) mandate strict barrier and decontamination solutions. Its recurring Services and Consumables segment-including biological indicators, lab services, and lifecycle support-provides a steady aftermarket revenue stream tied to the installed base of equipment.
- Pharma sterile manufacturing capex drives isolator equipment order growth
- Services and Consumables segment expansion lifts recurring revenue mix and margins
- Stricter GMP and aseptic regulations boost demand for decontamination and contamination control
| Net Income: 30.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 7.36 > 1.0 |
| NWC/Revenue: -21.63% < 20% (prev 7.98%; Δ -29.61% < -1%) |
| CFO/TA 0.12 > 3% & CFO 57.9m > Net Income 30.0m |
| Net Debt (47.0m) to EBITDA (58.4m): 0.81 < 3 |
| Current Ratio: 0.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (22.5m) vs 12m ago -0.02% < -2% |
| Gross Margin: 69.15% > 18% (prev 72.53%; Δ -3.37% > 0.5%) |
| Asset Turnover: 84.33% > 50% (prev 87.06%; Δ -2.73% > 0%) |
| Interest Coverage Ratio: 4.93 > 6 (EBIT TTM 44.4m / Interest Expense TTM 9.01m) |
| A: -0.16 (Total Current Assets 131.4m - Total Current Liabilities 210.0m) / Total Assets 480.0m |
| B: 0.01 (Retained Earnings 7.02m / Total Assets 480.0m) |
| C: 0.10 (EBIT TTM 44.4m / Avg Total Assets 430.8m) |
| D: 0.32 (Book Value of Equity 113.7m / Total Liabilities 354.6m) |
| Altman-Z'' = 0.00 = B |
| DSRI: 1.50 (Receivables 29.3m/17.8m, Revenue 363.3m/332.1m) |
| GMI: 1.05 (GM 72.53% / 69.15%) |
| AQI: 16.30 (AQ_t 0.32 / AQ_t-1 0.02) |
| SGI: 1.09 (Revenue 363.3m / 332.1m) |
| TATA: -0.06 (NI 30.0m - CFO 57.9m) / TA 480.0m) |
| Beneish M = 6.57 (Cap -4..+1) = D |
As of October 10, 2026, the stock is trading at CHF 70.70 with a total of 31,553 shares traded. Over the past week, the price has changed by +4.28%, over one month by +11.16%, over three months by +27.16% and over the past year by +25.49%.
Current recommended Stop Loss: 64.70 (which is 8.5% or 2.8 ATR below the current price).
SKAN has no consensus analysts rating.
P/E Trailing = 52.9323
P/E Forward = 62.8931
P/S = 4.3574
P/B = 13.648
Revenue TTM = 363.3m CHF
EBIT TTM = 44.4m CHF
EBITDA TTM = 58.4m CHF
Long Term Debt = 125.1m CHF (from longTermDebt, last fiscal year)
Short Term Debt = 1.09m CHF (from shortTermDebt, last quarter)
Debt = 135.5m CHF (from shortLongTermDebtTotal, last quarter) + Leases 4.83m
Net Debt = 47.0m CHF (calculated: Debt 135.5m - CCE 88.5m)
Enterprise Value = 1.63b CHF (1.58b + Debt 135.5m - CCE 88.5m)
Interest Coverage Ratio = 4.93 (Ebit TTM 44.4m / Interest Expense TTM 9.01m)
EV/FCF = 214.6x (Enterprise Value 1.63b / FCF TTM 7.59m)
FCF Yield = 0.47% (FCF TTM 7.59m / Enterprise Value 1.63b)
FCF Margin = 2.09% (FCF TTM 7.59m / Revenue TTM 363.3m)
Net Margin = 8.25% (Net Income TTM 30.0m / Revenue TTM 363.3m)
Gross Margin = 69.15% ((Revenue TTM 363.3m - Cost of Revenue TTM 112.0m) / Revenue TTM)
Gross Margin QoQ = 70.89% (prev 67.72%)
Tobins Q-Ratio = 3.40 (Enterprise Value 1.63b / Total Assets 480.0m)
Interest Expense / Debt = 6.65% (Interest Expense 9.01m / Debt 135.5m)
Taxrate = 11.72% (4.15m / 35.4m)
NOPAT = 39.2m (EBIT 44.4m * (1 - 11.72%))
Current Ratio = 0.53 (Total Current Assets 131.4m / Total Current Liabilities 249.5m)
Debt / Equity = 1.19 (Debt 135.5m / totalStockholderEquity, last quarter 113.7m)
Debt / EBITDA = 0.81 (Net Debt 47.0m / EBITDA 58.4m)
Debt / FCF = 6.19 (Net Debt 47.0m / FCF TTM 7.59m)
Total Stockholder Equity = 150.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.96% (Net Income 30.0m / Total Assets 480.0m)
RoE = 19.94% (Net Income TTM 30.0m / Total Stockholder Equity 150.4m)
RoCE = 16.13% (EBIT 44.4m / Capital Employed (Equity 150.4m + L.T.Debt 125.1m))
RoIC = 8.49% (NOPAT 39.2m / Invested Capital 461.9m)
WACC = 7.83% (E(1.58b)/V(1.72b) * Re(8.0%) + D(135.5m)/V(1.72b) * Rd(6.65%) * (1-Tc(0.12)))
Discount Rate = 8.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -52.22 | Cagr: -0.01%
[DCF] Terminal Value 75.44% ; FCFF base≈7.59m ; Y1≈7.63m ; Y5≈8.08m
[DCF] Fair Price = 3.50 (EV 125.6m - Net Debt 47.0m = Equity 78.6m / Shares 22.5m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 96.91 | Revenue CAGR: 23.67% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.40 | Chg30d=+1.32% | Revisions=+0% | GrowthEPS=+94.4% | GrowthRev=+18.9%
EPS next Year (2027-12-31): EPS=1.84 | Chg30d=-0.04% | Revisions=+0% | GrowthEPS=+31.6% | GrowthRev=+15.4%
[Analyst] Revisions Ratio: +0% (up=2, down=2)